NEW

Now Available



NDC 24090-410-08

WAC \$190.00

Cardinal Health Order Entry Number 4350922



Nitroglycerin aerosol spray delivers

- **Symptom relief in less than 60 seconds** in 70% of patients vs 38% for tablets (*P*<.001)¹
- Fewer, less severe headaches in patients treated with aerosol spray¹
- Faster, greater, and longer vasodilation with aerosol spray compared to sublingual tablets²
- Everyday prophylaxis of exercise-induced angina³

Account Name	Order Entry Number
ABC	036-653
Cardinal Health	4350922
McKesson Corp.	1112465
Bellco	389950
Burlington Drug	213145
DIK Drug	441360
Harvard Drug	970500
HD Smith	237-0781
Kinray	

Account Name	Order Entry Number
Miami Luken	113-522
Morris & Dickson	96867
NC Mutual	824755
Prescription Supply	577825
RDC	10237485
Smith Drug	520445
Valley Drug	474106
Value Drug	840371

In most patients

See full Prescribing Information at

www.nitromist.com

Dosing Information for Patients

Priming NitroMist: After receiving a new prescription or refill, patients should remove the plastic cap, place forefinger on actuator button, and press 10 times. NitroMist is now primed for 6 weeks and ready to use. If not used for more than 6 weeks, the NitroMist bottle can be adequately reprimed with 2 sprays.

Taking NitroMist: Patient should be sitting down. After removing the cap, bring the spray opening as close to the mouth as possible. Press actuator button firmly to deliver the full 400-mcg dose. NitroMist can be sprayed on or under the tongue and should not be inhaled. Adequate pressure must be applied to activate metered valve.

For complete dosing instructions, patients can visit www.nitromist.com

Please see Brief Summary of Prescribing Information on adjacent page.

References: 1. Vandenburg MJ, Griffiths GK, Brandman S. Sublingual nitroglycerin or spray in the treatment of angina. Br J Clin Pract. 1986;40(12):524-527. 2. Ducharme A, Dupuis J, McNicoll S, et al. Comparison of nitroglycerin lingual spray and sublingual tablet on time of onset and duration of brachial artery vasodilation in normal subjects. Am J Cardiol. 1999;84(8):952-954. 3. Data on file, 1996, Akrimax Pharmaceuticals, LLC.



